iSpecimen Inc. Proceeds from Sale and Maturity of Debt Securities, Available-for-sale
iSpecimen Inc. (ISPC) reported Proceeds from Sale and Maturity of Debt Securities, Available-for-sale of $3.15 million for the 12-month period ending 2024-12-31, per its 10-K filed 2026-04-01.
Financial Statements › Cash Flow › Investing Activities
us-gaap:ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities · last filed 2026-04-01
- iSpecimen Inc. proceeds from sale and maturity of debt securities, available-for-sale for the quarter ending 2024-12-31 was $0.00, a 100.00% decline year-over-year.
- iSpecimen Inc. proceeds from sale and maturity of debt securities, available-for-sale for the quarter ending 2024-09-30 was $0.00, a 100.00% decline year-over-year.
- iSpecimen Inc. proceeds from sale and maturity of debt securities, available-for-sale for the quarter ending 2024-06-30 was $467.32K.
- iSpecimen Inc. proceeds from sale and maturity of debt securities, available-for-sale for the quarter ending 2024-03-31 was $2.68M.
- iSpecimen Inc. proceeds from sale and maturity of debt securities, available-for-sale for fiscal 2024 was $3.15M, a 70.16% decline from fiscal 2023.
- iSpecimen Inc. proceeds from sale and maturity of debt securities, available-for-sale for fiscal 2023 was $10.56M.
| Period end | Proceeds from Sale and Maturity of Debt Securities, Available-for-sale 3 month | Proceeds from Sale and Maturity of Debt Securities, Available-for-sale 6 month | Proceeds from Sale and Maturity of Debt Securities, Available-for-sale 9 month | Proceeds from Sale and Maturity of Debt Securities, Available-for-sale 12 month |
|---|---|---|---|---|
| 2024-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2026-04-01 | $0.00 derived: sum of 2 quarters · filed 2026-04-01 | $467.32K derived: sum of 3 quarters · filed 2026-04-01 | $3.15M 10-K · filed 2026-04-01 |
| 2024-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-17 | $467.32K derived: sum of 2 quarters · filed 2025-11-17 | $3.15M 10-Q · filed 2025-11-17 | $6.36M derived: sum of 4 quarters · filed 2025-11-17 |
| 2024-06-30 | $467.32K derived: 10-Q 6 month − 10-Q 3 month · filed 2025-08-14 | $3.15M 10-Q · filed 2025-08-14 | $6.36M derived: sum of 3 quarters · filed 2025-08-14 | $12.17M derived: sum of 4 quarters · filed 2025-08-14 |
| 2024-03-31 | $2.68M 10-Q · filed 2025-05-19 | $5.89M derived: sum of 2 quarters · filed 2025-05-19 | $11.71M derived: sum of 3 quarters · filed 2025-05-19 | |
| 2023-12-31 | $3.21M derived: 10-K 12 month − 10-Q 9 month · filed 2025-04-14 | $9.02M derived: sum of 2 quarters · filed 2025-04-14 | $10.56M 10-K · filed 2025-04-14 | |
| 2023-09-30 | $5.82M derived: 10-Q 9 month − 10-Q 6 month · filed 2024-11-07 | $7.35M 10-Q · filed 2024-11-07 | ||
| 2023-06-30 | $1.53M 10-Q · filed 2024-08-06 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| FOXO TECHNOLOGIES INC. (FOXO) | United States | $0.000B | -277.71 |
| OneMedNet Corp (ONMD) | $0.042B | ||
| bioAffinity Technologies, Inc. (BIAF) | United States | $0.063B | |
| MAXCYTE, INC. (MXCT) | United States | $0.124B | -3.68 |
| NRC HEALTH (NRC) | United States | $0.450B | 42.50 |
| OmniAb, Inc. (OABI) | United States | $0.698B | -8.05 |
| Absci Corp (ABSI) | United States | $1.775B | -14.92 |
| CHARLES RIVER LABORATORIES INTERNATIONAL, INC. (CRL) | United States | $14.060B | -43.97 |
| Medpace Holdings, Inc. (MEDP) | United States | $17.316B | 30.09 |
| INCYTE CORP (INCY) | United States | $24.855B | 13.14 |